Efficacy and safety of intravenous laronidase for mucopolysaccharidosis type I: A systematic review and meta-analysis.

Alícia Dorneles DornellesOsvaldo ArtigalásAndré Anjos da SilvaDora Lucia Vallejo ArdilaTaciane AlegraTiago Veiga PereiraFilippo Pinto E VairoIda Vanessa Doederlein Schwartz

Published in: PloS one (2017)

Our findings suggest that IV laronidase effectively reduces urinary GAGs excretion, hepatomegaly and LVMI, and can improve shoulder flexion in MPS I patients. Laronidase appears to be safe in the studied population.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
peritoneal dialysis
prognostic factors
high dose
replacement therapy
rotator cuff